描述
Sitagliptin and Metformin Hydrochloride Extended-Release Tablets are a fixed-dose combination widely used in experimental studies involving type 2 diabetes mellitus (T2DM). This dual-action formulation features a DPP-4 inhibitor (sitagliptin) and a biguanide (metformin)—making it highly relevant for glucose metabolism, insulin resistance, and incretin pathway research.
Developed by Qilu Pharmaceutical (Hainan) Co., Ltd., this compound is approved under H20253718 and is intended exclusively for in vitro or in vivo laboratory research.
?? Not for human or animal consumption. For experimental use only.
Product Parameters
Attribute | Details |
---|---|
Product Name | Sitagliptin and Metformin Hydrochloride ER Tablets |
Chinese Name | ??????????? |
CAS (Sitagliptin) | 486460-32-6 |
CAS (Metformin) | 657-24-9 |
Molecular Formula | C16H15F6N5O·C4H11N5·HCl |
Strength | [Specification to be confirmed – typically 50mg/500mg or 100mg/1000mg] |
Dosage Form | Extended-Release Tablets |
Approval Number | H20253718 (NMPA China) |
Product Code | 86905847001237 |
Manufacturer | Qilu Pharmaceutical (Hainan) Co., Ltd. |
Storage | Store below 25°C; avoid humidity |
Packaging | Boxed tablets (exact unit count TBD) |
Use Restriction | Laboratory use only |
Mechanism & Research Applications
This combination tablet works via two complementary mechanisms:
-
Sitagliptin inhibits DPP-4, increasing incretin hormones (GLP-1, GIP), enhancing insulin release and reducing glucagon in hyperglycemia.
-
Metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Research applications include:
-
Glucose metabolism and insulin resistance studies
-
Evaluation of incretin pathway regulation
-
Investigations in combination therapy vs monotherapy efficacy
-
Experimental models of T2DM progression and treatment resistance
-
Preclinical pharmacokinetic and bioavailability analysis
Observed Effects in Research
Studies using this combination have reported:
-
Enhanced insulin sensitivity
-
Reduced postprandial glucose spikes
-
Improved ?-cell preservation
-
Attenuated hepatic gluconeogenesis
-
Synergistic glycemic control vs monotherapies
Safety & Handling
-
Use: For in vitro and in vivo research only
-
Protective Measures: Wear gloves, lab coat, and eye protection
-
Storage: Keep sealed, dry, and below 25°C
-
Disposal: As per lab chemical protocols
Research Use Disclaimer
This product is intended strictly for laboratory research use only. It is not for human use, diagnosis, or treatment. Proper lab safety and handling procedures must be followed. Misuse is prohibited and may be subject to local regulations.
premi –
Thanks